Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance our new molecular targeted systemic radiotherapy agents, EMT‑100 and EMT‑101 ready for clinic development. Current investors and one new investor supported the round. EMT‑100 and EMT‑101 have … [Read more...] about Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, raised £3.1 million